27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) gained about 1.5 percent.
The following catalytic biotech events are set to occur this week:
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Conferences
- 2018 European Society of Cardiology Congress: Aug. 25-29 in Munich, Germany
- 13th European Congress on Epileptology: Aug. 26-30 in Vienna, Austria
- International Conference on Molecular Biology and Medicine: Aug. 27-28 in Dubai, UAE
- 8th Global Experts Meeting on Advances in Neurology and Neuropsychiatry: Aug. 27-28 in Tokyo, Japan
- 5th International Conference on Glycobiology & Glycoproteomics: Aug. 27-28 in Toronto, Canada
- 21st World Congress on Radiology & Cancer Research: Aug 27-28 in Toronto
- 14th International Conference on Clinical Gastroenterology and Hepatology: Aug. 29-30 in Toronto
- 5th International Conference on Neglected Tropical & Infectious Diseases: Aug. 29-30 in Boston
- 5th Annual Congress on Rare Diseases and Orphan Drugs: Aug. 29-30 in Boston
- 4th Annual Congress on Infectious Diseases: Aug. 29-30 in Boston
- 4th World Congress on Parkinsons & Huntington Disease: Aug. 29-30 in Zurich, Switzerland
- 4th International Conference on Epilepsy & Treatment: Aug. 29-30 in Zurich
- 32nd Annual World Dentistry Summit: Aug. 31-Sept. 1 in Boston
- 6th World Summit on Heart, Stroke & Neurological Disorders: Aug. 31-Sept. 1 in Boston
- 14th World Summit on Alzheimer's Disease, Dementia Care Research and Awareness: Aug. 31-Sept. 1 in Boston
PDUFA Dates
Tuesday
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) awaits FDA decision on Eravacycline, a fully synthetic fluorocycline being developed for complicated intra-abdominal infections.
Thursday
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The FDA is set to rule on Akcea Therapeutics Inc (NASDAQ:AKCA)'s NDA for Volanesorsen, a RNAi drug to treat patients with familial chylomicronemia syndrome. Akcea is a unit of Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Clinical Trial Results
Pfizer Inc. (NYSE:PFE) will present late-phase data for Tafamidis, a TTR amyloid cardiomyopathy medication, at the European Society of Cardiology Congress on Monday.
Esperion Therapeutics Inc (NASDAQ:ESPR) is due to release Phase 3 data for bempedoic acid/ezetimibe, being evaluated for hypercholesterolemia.
Xenon Pharmaceuticals Inc (NASDAQ:XENE) is due to present Phase 1 data for its epilepsy treatment candidate XEN101 at the European Congress on Epileptology.
TG Therapeutics Inc common stock (NASDAQ:TGTX) has scheduled the release of Phase 3 UNITY-CLL study's top-line data for its TG-1101 and TGR-1202 combo to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma for the end of summer 2018.
Related Links:
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.